Tony S. K. Mok, BMSc, MD, FRCPC

Tony SK Mok, MD, discusses the rationale for the phase 1 U31402-A-U102 trial in metastatic or unresectable non–small cell lung cancer.

Tony S. K. Mok, MD, BMSc, FRCPC, FASCO, discusses the importance of improving cancer research through collaboration as a Giant of Cancer Care®.

Tony S. K. Mok, MD, BMSc, FRCPC, discusses overall survival from the phase III ALEX trial in ALK-positive lung cancer.

Tony S.K. Mok, BMSc, MD, FRCPC, professor, Department of Clinical Oncology, Chinese University of Hong Kong, Prince of Wales Hospital Hong Kong, China, discusses how to improve the strategy of developing treatments for lung cancer.

Tony S.K. Mok, BMSc, MD, FRCPC, from the Chinese University of Hong Kong, discusses different plasma testing approaches for patients with lung cancer.